Treatment of Cognitive Disability in Schizophrenia With a GABA-A Alpha2/3 Receptor Agonist
Abstract
The purpose of this research study is to determine whether a short-term administration of an investigational study drug may provide evidence of improvement in cognitive functioning in a group of stable male subjects with schizophrenia.
Conditions: Schizophrenia.
Primary outcome: N-back Task - Reaction Time; N-back Task - Error Rate; AX Continuous Performance Test Task D-prime; Preparing to Overcome Prepotency (POP) Task - Reaction Time; Preparing to Overcome Prepotency Task - Error Rate.
Enrollment: 16 participants.
How strong is the evidence?
Evidence Hub reads this as a clinical trial, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 16 participants or records.
Read the paper
Related studies
- Diarylethenes for Memories and Switches
- Long-Term Potentiation and Memory
- Social Memory Studies: From “Collective Memory” to the Historical Sociology of Mnemonic Practices
- The Cognitive Neuroscience of Working Memory
- Memory aging and brain maintenance
- Effector and Memory CTL Differentiation
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.